Wedica100 mg

Approved Use

Wedica is a long-acting, once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is approved and marketed in Japan (and in a limited number of other Asian markets) rather than by the US FDA, so its regulatory status and availability outside those markets, including Bangladesh, should be confirmed locally before use.

Use in Combination Therapy

Wedica may be used as monotherapy or in combination with other classes of antidiabetic agents (for example, metformin, sulfonylureas, thiazolidinediones, or insulin) when diet, exercise, and a single agent do not achieve adequate glycemic control, under physician supervision.

Not Indicated For

Wedica is not indicated for the treatment of type 1 diabetes mellitus or for diabetic ketoacidosis, and it is not a substitute for insulin in patients who require insulin.

Each tablet contains Trelagliptin Succinate as the active pharmaceutical ingredient, typically formulated as 100 mg oral tablets (strength expressed as trelagliptin base equivalent). Formulation strengths and available pack sizes may vary by manufacturer and market; refer to the specific product label for exact composition and excipients.

Wedica is a selective, long-acting inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme, developed to allow once-weekly oral dosing for type 2 diabetes, in contrast to most other DPP-4 inhibitors (such as sitagliptin, vildagliptin, or linagliptin) which require once- or twice-daily dosing. It was developed to improve adherence and dosing convenience for patients with type 2 diabetes. Wedica was first approved in Japan (marketed as Zafatek) and has more limited global regulatory approval and clinical evidence compared to the widely used daily DPP-4 inhibitors.

Wedica belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, also known as "gliptins," which is a class of oral antidiabetic (antihyperglycemic) agents.

Mechanism

Trelagliptin Succinate works by selectively and reversibly inhibiting the DPP-4 enzyme, which is normally responsible for rapidly degrading the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, Trelagliptin Succinate increases circulating active incretin levels.

Effect

Elevated incretin levels increase glucose-dependent insulin secretion from pancreatic beta cells and suppress inappropriately elevated glucagon secretion from alpha cells, lowering blood glucose in a glucose-dependent manner. Because insulin release is glucose-dependent, the intrinsic hypoglycemia risk of Trelagliptin Succinate alone (i.e., not combined with insulin or a sulfonylurea) is low.

Duration of Action

Trelagliptin Succinate has a prolonged pharmacodynamic effect on DPP-4 inhibition that supports once-weekly dosing, distinguishing it from daily-dosed DPP-4 inhibitors.

Wedica is administered orally, once weekly, and may be taken with or without food. Tablets should be swallowed whole with water. Patients should be counselled to choose a fixed day of the week for dosing and to use a reminder system (e.g., calendar or phone alert) to avoid missed or duplicate doses, given the long once-weekly interval.

Insulin and Sulfonylureas

Combining Wedica with insulin or insulin secretagogues (e.g., sulfonylureas) increases the risk of hypoglycemia. A dose reduction of the insulin or sulfonylurea may be needed when co-administered with Wedica.

Other DPP-4 Inhibitors / Incretin-Based Therapies

Wedica should not be combined with other DPP-4 inhibitors or GLP-1 receptor agonists, as there is no established additional benefit and combined use has not been studied.

CYP-Mediated Interactions

Clinically significant pharmacokinetic drug-drug interactions mediated through major cytochrome P450 pathways have not been well established for Wedica; nonetheless, patients should inform their physician of all concurrent medications.

Common

• Nasopharyngitis (common cold-like symptoms)
• Gastrointestinal effects such as constipation, abdominal discomfort, or diarrhea
• Headache
• Hypoglycemia (mainly when combined with insulin or sulfonylureas — see Interactions)

Less Common but Clinically Important

• Acute pancreatitis — a rare but serious adverse effect reported with the DPP-4 inhibitor class; see Precautions and Warnings.
• Severe joint pain — reported with DPP-4 inhibitors as a class, sometimes severe or disabling; see Precautions and Warnings.
• Bullous pemphigoid and other skin reactions — rare, class-associated; see Precautions and Warnings.
• Signs of heart failure (e.g., swelling, unusual shortness of breath, rapid weight gain) — reported with some agents in the DPP-4 inhibitor class; see Precautions and Warnings.

Pregnancy: Data on the use of Wedica in pregnant women are limited. Wedica should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus; a physician should be consulted, and alternative, better-studied antidiabetic therapy (such as insulin) is generally preferred for glycemic control during pregnancy.

Lactation: It is not known whether Wedica is excreted in human breast milk. Because many drugs are excreted in breast milk and the effects on a nursing infant are unknown, a decision should be made, in consultation with a physician, whether to discontinue breastfeeding or discontinue Wedica, taking into account the importance of the drug to the mother.

Pancreatitis

Acute pancreatitis, including fatal cases, has been reported with DPP-4 inhibitors as a class. Patients should be observed for signs and symptoms of pancreatitis (persistent, severe abdominal pain, sometimes radiating to the back, with or without vomiting). If pancreatitis is suspected, Wedica should be discontinued promptly and appropriate management instituted.

Severe and Disabling Joint Pain

Severe and sometimes disabling joint pain has been reported in patients taking DPP-4 inhibitors, including Wedica. Onset can occur anywhere from one day to years after starting treatment. If new or worsening severe joint pain occurs, the patient should be evaluated and discontinuation of Wedica considered.

Bullous Pemphigoid

Bullous pemphigoid requiring hospitalization has been reported with DPP-4 inhibitors as a class. If a patient develops blistering or erosive skin lesions, Wedica should be discontinued and dermatologic evaluation and treatment sought.

Heart Failure

A heart failure signal has been observed with some members of the DPP-4 inhibitor class, though the evidence varies by specific agent and has not been consistently established for Wedica. Patients, particularly those with pre-existing heart failure or renal impairment, should be monitored for signs and symptoms of heart failure (e.g., unusual dyspnea, rapid weight gain, edema); if these develop, further use of Wedica should be reassessed.

Hypoglycemia with Combination Therapy

When Wedica is used with insulin or a sulfonylurea, the risk of hypoglycemia is increased; a lower dose of the insulin or sulfonylurea may be required (see Interactions).

Renal Impairment

Dose adjustment may be required in moderate to severe renal impairment (see Use in Special Populations).

Once-Weekly Dosing Schedule

Because Wedica is dosed only once weekly, patients require specific counselling on adherence and on avoiding missed or duplicate doses, since dosing errors have a longer-lasting impact than with daily agents.

Regional Approval Status

Wedica has a more limited global regulatory approval and clinical evidence base compared to daily-dosed DPP-4 inhibitors; it is primarily approved and used in Japan and select Asian markets. Prescribers and patients should confirm local regulatory status and availability before use.

Limited data exist on overdose with Wedica. Based on its mechanism and the class of drugs it belongs to, an overdose would primarily be expected to increase the risk of gastrointestinal upset and, particularly if combined with insulin or a sulfonylurea, hypoglycemia. In case of suspected overdose, seek immediate medical attention or contact a poison control center / emergency services. Supportive care and monitoring of blood glucose, and treatment of hypoglycemia if it occurs, are the mainstays of management; there is no specific antidote. Do not attempt to manage a suspected overdose with home remedies.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

Dose adjustment (e.g., reduction from 100 mg to 50 mg once weekly) may be required in patients with moderate to severe renal impairment or end-stage renal disease, as Wedica and/or its metabolites are renally eliminated; consult the prescribing physician for individualized dosing.

Hepatic Impairment

Data in patients with significant hepatic impairment are limited; Wedica should be used with caution in this population, with monitoring of glycemic control.

Elderly

Elderly patients may be at greater risk of renal impairment and hypoglycemia when Wedica is combined with insulin or sulfonylureas; use with appropriate monitoring and consider age-related decline in renal function when dosing.

Pediatric Patients

Safety and efficacy of Wedica have not been established in patients under 18 years of age; see Pediatric Uses.

Wedica is typically used long-term as ongoing maintenance therapy for chronic glycemic control in type 2 diabetes mellitus, for as long as the treating physician determines it remains effective, well-tolerated, and clinically indicated based on periodic reassessment of glycemic control (e.g., HbA1c) and tolerability.

Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins); Oral antidiabetic / antihyperglycemic agents

Trelagliptin Succinate selectively and reversibly inhibits the DPP-4 enzyme, prolonging the activity of endogenous incretin hormones (GLP-1 and GIP), which increases glucose-dependent insulin secretion and suppresses glucagon secretion, thereby lowering blood glucose without a high intrinsic risk of hypoglycemia when used alone.

The safety and efficacy of Wedica have not been established in pediatric patients (under 18 years of age). Wedica is therefore not recommended for use in children or adolescents outside of a clinical trial setting, and alternative, well-studied antidiabetic therapies should be considered for pediatric type 2 diabetes under specialist supervision.